Photo Credit: Arif biswas
The following is a summary of “Impact of chromosomal aberrations detected by chromosome banding analysis in symptomatic Waldenström’s macroglobulinemia,” published in the October 2024 issue of Hematology by Ito et al.
Waldenström’s macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma associated with MYD88 L265P (MYDL265P) and CXCR4 mutations (CXCR4Mut) mutations, but the impact of chromosomal aberrations (CA) remains unclear.
Researchers conducted a retrospective study to examine the clinicopathologic features and prognostic impact of chromosomal aberrations in patients with symptomatic Waldenström’s macroglobulinemia (sWM).
They analyzed bone marrow samples from 35 symptomatic patients with WM collected between April 2010 and March 2024 using droplet digital PCR, fluorescence in situ hybridization (FISH), and chromosome banding analysis (CBA) (G-banding method). Relationships between chromosomal aberrations and clinical features, including time to next treatment (TTNT), were evaluated (P values: anemia P=0.04, hypoalbuminemia P=0.007, M-protein and IgM P=0.03).
The results showed CA (detected by CBA in 9 of 34 patients [26%]) were associated with more severe anemia (P=0.04), hypoalbuminemia (P=0.007), and higher levels of serum M-protein and IgM (P=0.03). The median TTNT was shorter in patients with CA (27 months) than those without (68 months).
They concluded that CA in patients with sWM may indicate more aggressive disease and predict shorter TTNT.
Source: link.springer.com/article/10.1007/s00277-024-06041-y
